Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Fluvoxamine Shows Significant Difference against Placebo for Pediatric Obsessive-Compulsive Disorder in PIII Study: Meiji Seika Pharma
Meiji Seika Pharma announced on September 11 the results from a PIII clinical study of the antidepressant fluvoxamine in pediatric patients with obsessive-compulsive disorder (OCD). The primary endpoint of the 10 week double-blind comparative study is to evaluate the efficacy…
To read the full story
Related Article
BUSINESS
- Tanabe Gets Thai Approval for Diabetes Drug Canalia
June 30, 2026
- Kissei Discussing Japan Response after EU Panel Recommends Pulling Tavneos Approval
June 29, 2026
- Sanofi Files Venglustat for Gaucher Disease in Japan
June 29, 2026
- Santen’s Myopia Drug Ryjusea Wins Nod in Philippines
June 29, 2026
- Toho Shareholders Approve Trigger for 3D Defense Measures
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…